Li-Tzong Chen, M.D., Ph.D

Li-Tzong Chen, M.D., Ph.D

National Institute of Cancer Research
National Health Research Institutes , Taiwan
Investigator and Attending Physician
2F, No. 367, Sheng-Li Road, 70456 Tainan, Taiwan

Get in Touch

Email: leochen@nhri.org.tw

Education

1975 - 1982
M.D., Kaohsiung Medical College, Kaohsiung, Taiwan
 
1992 - 2001
Ph.D., Post-graduate School, Kaohsiung Medical University
 

Job History

2012/09
Professor, Taipei Medical University
 
2008/03 - present
Depeuty Director, National Institute of Cacer Research, National Health Research Institiutes
 
2007/07 - present
Attending Physician, Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan
 
2006/08 - 2007/07
Adjunct Attending Physician, Department of Internal Medicine, Triservice General Hospital, Taipei
 
2006/01 - present
Investigator, National Institute of Cacer Research, National Health Research Institiutes
 
2005/10 - 2005/11
Visiting Investigator, Cancer Therapy Evaluational Program (CTEP), National Cancer Institute, NIH, USA
 
2005/02 - present
Associate Professor, College of Medicine, Kaohsiung Medical University
 
2002/08 - 2006/01
Associate Investigator, National Institute of Cancer Research, National Health Research Institiutes
 
1995/08 - present
Attending Physician, National Institute of Cancer Research, National Health Research Institutes
 
1995/08 - 2009/09
Adjunct Attending Physician, Department of Oncology, National Taiwan University Hospital, Taipei
 
1995/08 - 2006/07
Adjunct Attending Physician, Department of Internal Medicine, Veteran General Hospital, Taipei
 
1992/08 - 2005/02
Lecturer, Internal Medicine, Kaohsiung Medical University
 
1988/08 - present
Attending Physician, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung
 
1988/04 - 1990/03
Fellowship, Medical Oncology Training Program Institute of Biomedical Science, Academia Sinica, Taipei
 
1987/08 - 1988/07
Chief Resident, Department of Medicine, Kaohsiung Medical College Hospital
 
1984/08 - 1987/07
Residency training, Department of Medicine, Kaohsiung Medical College Hospital
 
1981/08 - 1982/07
Internship, Kaohsiung Medical College Hospital
 

Honors and Awards

2010
NHRI Outstanding Research Achievement Award
 
2009
Distinguished Scholar Award, National Health Research Insitutes
 
2009
Thesis advisor Award of College Student Research, National Science Concil
 
2006
Outstanding Research Award, Kaohisung Medical University
 
2005
Outstanding Research Award, Kaohisung Medical University
 
2005
Invited speaker for the“Controversy of adjuvant chemotherapy for gastriccancer”in the 18th Asian -Pacific Cancer Conference (APCC), Seoul, Korea,September 7-9
 
2004
Invited speaker for the International Symposium “The Cooperation in Asia”,“The review and prospect of gastric cancer chemotherapy in Taiwan”in the76th Annual Meeting of Japanese Gastric Cancer Association (JGCA),Yonago, Japan, March 4-6
 
2003
Outstanding research award, Chien-Ten Hsu Cancer Research Foundation
 
2003
Clinical Research Award, the 8th Annual Meeting of Joint Taiwan Oncology Societies."Medical therapy in gastrointestinal cancer: the NHRI studies", Taipei, Taiwan
 
2001
Excellent Award of Poster Presentation, 6th Annual Jointed Meeting of Taiwan Oncology Societies."Phase I and PK study of thalidomide in advanced hepatocellular carcinoma"
 
2000
Excellent Award of Poster Presentation, 5th Annual Jointed Meeting of Taiwan Oncology Societies."Anti-Helicobater pylori therapy in early-stage low-grade & high-grade MALT lymphoma of the stomach"
 
1999
Excellent Award of Poster Presenation, 4th Annual Joined Meeting of Taiwan Oncology Societies. "Dose-escalation study of weekly docetaxel plus cisplatin and 24-hour infusion of high-dose fluorouracil and leucovorin in advanced gastric cancer"
 

Publications

  1. Chen, L. T., C. C. Chen, T. C. Tsou, W. Y. Pan, C. C. Kuo, J. F. Liu, S. C. Yeh, F. Y. Tsai, H. R. Hsieh and J. Y. Chang. "Combined Modalities of Resistance in an Oxaliplaitin-Resistant Human Gastric Cancer Cell Line with Enhanced Sensitivity." Ejc Supplements 4, no. 12 (2006): 59-59.
  2. Yang, T. S., S. N. Lu, Y. Chao, I. S. Sheen, C. C. Lin, T. E. Wang, S. C. Chen, J. H. Wang, L. Y. Liao, J. A. Thomson, J. Wang-Peng, P. J. Chen and L. T. Chen. "A Randomised Phase Ii Study of Pegylated Arginine Deiminase (Adi-Peg 20) in Asian Advanced Hepatocellular Carcinoma Patients." British Journal of Cancer 103, no. 7 (2010): 954-960.
  3. Yeh, K., Y. C. Shen, C. P. Li, C. J. Yen, Y. L. Lin, Z. Z. Lin, L. T. Chen, W. C. Su, Y. Chao and A. L. Cheng. "Phase Ii Study of Low-Dose Everolimus Plus Weekly Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin for First-Line Treatment of Metastatic or Recurrent Gastric Cancers." European Journal of Cancer 47, (2011): S467-S467.
  4. Chen, L. T., Y. S. Hsueh, C. C. Yen, N. Y. Shih, N. J. Chiang and C. F. Li. "Involvement of Autophagy in Endogenous and Nvp-Auy922-Induced C-Kit Degradation in Both Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Cells." Annals of Oncology 23, (2012): 28-28.
  5. Chen, L. T., S. H. Kuo, K. H. Yeh, M. S. Wu, C. W. Lin, P. N. Hsu, H. P. Wang and A. L. Cheng. "Front-Line Antibiotic Therapy in Early-Stage H. Pylori-Positive Gastric Diffuse Large B-Cell Lymphomas with or without Malt Features." Annals of Oncology 23, (2012): 105-105.
  6. Cheng, S. L., Y. H. Lin, S. W. Lee, T. Lee, H. Chen, J. C. Hu and L. T. Chen. "Fabrication of Size-Tunable, Periodic Si Nanohole Arrays by Plasma Modified Nanosphere Lithography and Anisotropic Wet Etching." Applied Surface Science 263, (2012): 430-435.
  7. Cheng, S. L., T. L. Hsu, T. Lee, S. W. Lee, J. C. Hu and L. T. Chen. "Characterization and Kinetic Investigation of Electroless Deposition of Pure Cobalt Thin Films on Silicon Substrates." Applied Surface Science 264, (2013): 732-736.
  8. Chen, L. T., H. J. Tsai, S. H. Kuo and A. L. Cheng. "Auy922, a Novel Hsp90 Inhibitor Effective against Abc-Dlbcl and Malt Lymphoma Cells Harboring Genetic Alteration-Associated Nf-Kappa B Activation." Annals of Oncology 24, (2013): 24-25.
  9. Shiah, H. S., C. Y. Chen, C. Y. Dai, C. F. Hsiao, Y. J. Lin, W. C. Su, J. Y. Chang, J. Whang-Peng, P. W. Lin, J. D. Huang and L. T. Chen. "Randomised Clinical Trial: Comparison of Two Everolimus Dosing Schedules in Patients with Advanced Hepatocellular Carcinoma." Alimentary Pharmacology & Therapeutics 37, no. 1 (2013): 62-73
  10. Ko, A. H., M. A. Tempero, Y. S. Shan, W. C. Su, Y. L. Lin, E. Dito, A. Ong, Y. W. Wang, C. G. Yeh and L. T. Chen. "A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (Pep02, Mm-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer." British Journal of Cancer 109, no. 4 (2013): 920-925.
  11. Finn, R. S., R. T. Poon, T. Yau, H. J. Klumpen, L. T. Chen, Y. K. Kang, T. Y. Kim, C. Gomez-Martin, C. Rodriguez-Lope, T. Kunz, T. Paquet, U. Brandt, D. Sellami and J. Bruix. "Phase I Study Investigating Everolimus Combined with Sorafenib in Patients with Advanced Hepatocellular Carcinoma." J Hepatol 59, no. 6 (2013): 1271-7.
  12. Wang, Y. K., D. Y. Hwang, S. S. Wang, S. J. Hwang, L. T. Chen and M. C. Kuo. "Terlipressin-Induced Hyponatremic Encephalopathy in a Noncirrhotic Patient." Kaohsiung J Med Sci 29, no. 12 (2013): 691-4.
  13. Roy, A. C., S. R. Park, D. Cunningham, Y. K. Kang, Y. Chao, L. T. Chen, C. Rees, H. Y. Lim, J. Tabernero, F. J. Ramos, M. Kujundzic, M. B. Cardic, C. G. Yeh and A. de Gramont. "A Randomized Phase Ii Study of Pep02 (Mm-398), Irinotecan or Docetaxel as a Second-Line Therapy in Patients with Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma." Annals of Oncology 24, no. 6 (2013): 1567-1573.
  14. Kuo, S. H., L. T. Chen, C. W. Lin, M. S. Wu, P. N. Hsu, H. J. Tsai, C. Y. Chu, Y. S. Tzeng, H. P. Wang, K. H. Yeh and A. L. Cheng. "Detection of the Helicobacter Pylori Caga Protein in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Cells: Clinical and Biological Significance." Blood Cancer Journal 3, (2013).
  15. Chiang, N. J., L. T. Chen, C. R. Tsai and J. S. Chang. "The Epidemiology of Gastrointestinal Stromal Tumors in Taiwan, 1998-2008: A Nation-Wide Cancer Registry-Based Study." BMC Cancer 14, no. 1 (2014): 102
  16. Hong, K. J., D. C. Wu, K. H. Cheng, L. T. Chen and W. C. Hung. "Reck Inhibits Stemness Gene Expression and Tumorigenicity of Gastric Cancer Cells by Suppressing Adam-Mediated Notch1 Activation." J Cell Physiol 229, no. 2 (2014): 191-201.
  17. Lee, S. W., C. Y. Lin, Y. F. Tian, D. P. Sun, L. C. Lin, L. T. Chen, C. H. Hsing, C. T. Huang, H. P. Hsu, H. Y. Huang, L. C. Wu, C. F. Li and Y. L. Shiue. "Overexpression of Cdc28 Protein Kinase Regulatory Subunit 1b Confers an Independent Prognostic Factor in Nasopharyngeal Carcinoma." APMIS 122, no. 3 (2014): 206-14.

 

Recent Activity

[Academic Seminar] Kaohsiung Medical University Department of Pharmacy 67th Anniversary Celebration and International Seminar - 10/13/2024 (Sun.)

- 2024-10-01

 1★★ Department of Pharmacy 67th Anniversary Celebration and International Seminar ★★ 【 Time 】10/13...
[Research Highlights]Neuron-derived neurotensin and pancreatic cancer-derived semaphorin 3A severe pancreatic cancer and are counteracted by small molecule inhibitors

- 2024-06-28

陳立宗 英文Neuron-derived neurotensin and pancreatic cancer-derived semaphorin 3A severe pancreatic cancer a...
[Research Highlights]RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line therapy: a multicenter study

- 2024-06-28

王照元 圖一英RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line therapy: a mu...
Go to top